Literature DB >> 22495387

Cancer and innate immune system interactions: translational potentials for cancer immunotherapy.

Yanan Liu1, Gang Zeng.   

Abstract

Passive immunotherapy, including adoptive T-cell therapy and antibody therapy, has shown encouraging results in cancer treatment lately. However, active immunotherapy of solid cancers remains an elusive goal. It is now known that the human innate immune system recognizes pathogen-associated molecular patterns conserved among microbes or damage-associated molecular patterns released from tissue injuries to initiate adaptive immune responses during infection and tissue inflammation, respectively. In contrast, how the innate immune system recognizes endogenously arising cancer remains poorly understood at the molecular level, which poses a significant roadblock to the development of active cancer immunotherapy. We hereby review the current knowledge of how solid cancers directly and indirectly interact with cells of the human innate immune system, with a focus on the potential effect of such interactions to the resultant adaptive immune responses against cancer. We believe that understanding cancer and innate immune system interactions may allow us to better manipulate the adaptive immune system at the molecular level to develop effective active immunotherapy against cancer. Current and future perspectives in clinical development that exploits these molecular interactions are discussed.

Entities:  

Mesh:

Year:  2012        PMID: 22495387      PMCID: PMC3331796          DOI: 10.1097/CJI.0b013e3182518e83

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  140 in total

1.  Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4.

Authors:  Geoffrey B Johnson; Gregory J Brunn; Yuzo Kodaira; Jeffrey L Platt
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

2.  Macrophage recognition of ICAM-3 on apoptotic leukocytes.

Authors:  O D Moffatt; A Devitt; E D Bell; D L Simmons; C D Gregory
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

Review 3.  Immune functions encoded by the natural killer gene complex.

Authors:  Wayne M Yokoyama; Beatrice F M Plougastel
Journal:  Nat Rev Immunol       Date:  2003-04       Impact factor: 53.106

Review 4.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

5.  Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination.

Authors:  Wolfgang Kratky; Caetano Reis e Sousa; Annette Oxenius; Roman Spörri
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

6.  Identification of a factor that links apoptotic cells to phagocytes.

Authors:  Rikinari Hanayama; Masato Tanaka; Keiko Miwa; Azusa Shinohara; Akihiro Iwamatsu; Shigekazu Nagata
Journal:  Nature       Date:  2002-05-09       Impact factor: 49.962

7.  Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination.

Authors:  P Fagone; D J Shedlock; H Bao; O U Kawalekar; J Yan; D Gupta; M P Morrow; A Patel; G P Kobinger; K Muthumani; D B Weiner
Journal:  Gene Ther       Date:  2011-05-05       Impact factor: 5.250

8.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

Authors:  Eynav Klechevsky; Rimpei Morita; Maochang Liu; Yanying Cao; Sebastien Coquery; Luann Thompson-Snipes; Francine Briere; Damien Chaussabel; Gerard Zurawski; A Karolina Palucka; Yoram Reiter; Jacques Banchereau; Hideki Ueno
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

9.  Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation.

Authors:  Masafumi Nakayama; Hisaya Akiba; Kazuyoshi Takeda; Yuko Kojima; Masaaki Hashiguchi; Miyuki Azuma; Hideo Yagita; Ko Okumura
Journal:  Blood       Date:  2009-02-17       Impact factor: 22.113

10.  Molecular cloning of the NK1.1 antigen, a member of the NKR-P1 family of natural killer cell activation molecules.

Authors:  J C Ryan; J Turck; E C Niemi; W M Yokoyama; W E Seaman
Journal:  J Immunol       Date:  1992-09-01       Impact factor: 5.422

View more
  62 in total

1.  Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survival.

Authors:  Sen Yang; Dongfang Tang; Yu C Zhao; Hongliang Liu; Sheng Luo; Thomas E Stinchcombe; Carolyn Glass; Li Su; Sipeng Shen; David C Christiani; Qiming Wang; Qingyi Wei
Journal:  Int J Cancer       Date:  2019-12-19       Impact factor: 7.396

Review 2.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

Review 3.  Cancer therapies in HIV cure research.

Authors:  Thomas A Rasmussen; Jenny L Anderson; Fiona Wightman; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

Review 4.  Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.

Authors:  Sarju Ganatra; Joseph R Carver; Salim S Hayek; Bonnie Ky; Monika J Leja; Daniel J Lenihan; Carrie Lenneman; Negaresh Mousavi; Jae H Park; Miguel Angel Perales; Thomas D Ryan; Marielle Scherrer-Crosbie; Richard M Steingart; Eric H Yang; Vlad Zaha; Ana Barac; Jennifer E Liu
Journal:  J Am Coll Cardiol       Date:  2019-12-24       Impact factor: 24.094

Review 5.  Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

Authors:  David P Carbone; David R Gandara; Scott J Antonia; Christoph Zielinski; Luis Paz-Ares
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

6.  Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment.

Authors:  Thomas A Mace; Mark Bloomston; Gregory B Lesinski
Journal:  Oncoimmunology       Date:  2013-05-07       Impact factor: 8.110

7.  Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models.

Authors:  Julie K Jang; Leslie A Khawli; David C Canter; Peisheng Hu; Tian H Zhu; Brian W Wu; Trevor E Angell; Zhongjun Li; Alan L Epstein
Journal:  Cancer Immunol Immunother       Date:  2016-03-09       Impact factor: 6.968

8.  Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML.

Authors:  Nathaniel J Buteyn; Ramasamy Santhanam; Giovanna Merchand-Reyes; Rakesh A Murugesan; Gino M Dettorre; John C Byrd; Anasuya Sarkar; Sumithira Vasu; Bethany L Mundy-Bosse; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Immunol       Date:  2020-02-24       Impact factor: 5.422

Review 9.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

10.  Chemotaxis-driven assembly of endothelial barrier in a tumor-on-a-chip platform.

Authors:  Aereas Aung; Jomkuan Theprungsirikul; Han Liang Lim; Shyni Varghese
Journal:  Lab Chip       Date:  2016-04-21       Impact factor: 6.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.